Halozyme Therapeutics Inc.
HALO
Get informed when a big investor buys or sells
+ FollowMarket Cap$13.34B
Close$
$96.61
16.2% downside
Current Fair Value
16.2% downsideOvervalued by 16.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $13.34 Billion |
|---|---|
| Enterprise Value | $15.32 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.64 |
| Beta | 0.88 |
| Outstanding Shares | 117,274,000 |
Return
| Return on Equity | 288.13% |
|---|---|
| Return on Assets | 16.05% |
| Return on Invested Capital | 42.54% |
Valuation & Multiples
| P/E Ratio | 31.95 |
|---|---|
| PEG | 81.48 |
| Price to Sales | 8.23 |
| Price to Book Ratio | 115.22 |
| Enterprise Value to Revenue | 9.21 |
| Enterprise Value to EBIT | 16.13 |
| Enterprise Value to Net Income | 37 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 14.95 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$1.79
Average shareholder expectationRevenue Estimate
$402.28 M
Average shareholder expectationNext Earnings Call
Expected Date
November 2, 2026
EPS Estimate
$2.25
Average shareholder expectationRevenue Estimate
$482.28 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6167▼ 16.33% |
|---|---|
| Total Calls | 450,800▲ 41.32% |
| Total Puts | 278,000▲ 11.74% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 106.23%▲ 4.27% |
|---|---|
| Total Invested | $9.72B▲ 24.85% |
| Investors Holding | 688▲ 35.00% |
ESG Score
No data
About Halozyme Therapeutics Inc.
CEO: Helen Torley